Advances in Hyperprogressive Disease in Patients with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy / 中国肺癌杂志

Hyperprogressive disease (HPD) is a novel pattern of progression caused by immune checkpoint inhibitors (ICIs). It is characterized by a dramatic tumor surge and is associated with poor clinical outcomes. Up to now, the definition of HPD is still controversial across various studies. Although it has been indicated that HPD has related to multiple clinicopathological features and genetic alterations, it is lack of biomarker to predict its occurrence, and the potential mechanism remains unknown. This review is to summarize current data on HPD specialized in the field of non-small cell lung cancer. And we expect to provide helpful clinical strategies for oncologists using ICIs.
.

Advances in hyperprogressive disease of PD-1/PD-L1 antibody drugs and rational drug therapy / 药学学报

With the significant breakthrough that programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) antibody drugs achieved promising clinical outcomes across various tumor types, immunotherapy targeting immune checkpoint has been considered a promising way to treat cancer. However, most recently studies suggest that the hyperprogressive disease occurred frequently during the therapy of using PD-1/PD-L1 antibody drugs and has become an urgent problem to be solved. In this review, we summarize the progress and potential reasons of hyperprogressive disease caused by PD-1/PD-L1 blockade, and further discuss its application based on the rational use of biomarkers for searching the benefit patients.

Hyperprogressive disease in immunotherapy for non-small cell lung cancer / 肿瘤

Immunotherapy launched an entirely new era for human health and cancer treatment by enhancing the body’s immune system. Immunotherapy can not only eliminate tumor cells in the body to suppress “tumor immune escape”, but also benefit the survival of a subset of patients with non-small cell lung cancer (NSCLC). However, some clinical trials have shown that immunotherapy has limited efficacy, even accelerates tumor growth rate, increases tumor burden and produces new lesions; clinically, this is called “hyperprogressive disease (HPD)". At present, HPD is not uncommon in the treatment of NSCLC. The mechanism underlying current findings remains to be characterized. There is still a lot of controversy about HPD, lacking new therapeutic evaluation criteria for immunotherapy, and no potential biomarkers and molecular mechanisms have been identified. This paper systematically reviewed the clinical research progress in HPD after anti-NSCLC immunotherapy, the prediction of biomarkers, the mechanism of HPD occurrence, and the identification of pseudo progression.

Hyperprogressive disease in cancer patients with immune checkpoint inhibitor therapy and its coping strategies / 中国肿瘤生物治疗杂志

@#Successful targeting and inhibition of the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint pathways by monoclonal antibody stimulates an immune response against tumors, has led to a rapidly expanding repertoire of immune checkpoint inhibitors (ICIs) for the treatment of various cancers. Immune checkpoint therapy has dramatically changed the therapeutic landscape of certain types of cancers. However, hyperprogressive disease (HPD) is emerging as a new pattern of progression in cancer patients treated with ICIs, characterized as an absolute increase in the tumor growth rate exceeding 50% per month. This article discusses the concept of HPD, hypotheses as to the underlying biology, and what needs to be done to better understand and identify strategies to prevent or overcome HPD related to checkpoint blockade therapy.